PROs in Chronic Cervical Pain Patients With Accompanying Upper Limb Radiating Pain Treated With Pregabalin
CompletedNCT02868359
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the effect of pregabalin on patient reported outcomes compared with conventional analgesic care in chronic cervical pain patients with accompanying upper limb radiating pain (neuropathic component) treated in primary care settings under routine clinical practice.
Study details
- Official title
- Patient-Reported-Outcomes In Chronic Cervical Pain Patients With Accompanying Upper Limb Radiating Pain (Neuropathic Component) Treated With Pregabalin In Primary Care Settings
- Conditions
- Cervical Pain
- Neuropathic Pain
- Radiating Pain
- Interventions
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Organization
- Pfizer
- Start date
- 2016-10
- Primary completion
- 2017-10-24
- Sex
- All
- Age range
- from 20 Years
- Results posted
- No results posted in this snapshot
- Countries
- Japan
- Total sites listed
- 33
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: Subject who received the enough study information and signed informed consent form. Subject who had chronic pain with accompanying radiating pain to the superior limb beyond the elbow. Subject is male or female patient ≧20 years old. Subject who reported neck pain with accompanying radiating pain to superior limb (12 weeks or greater in duration at Visit 0). Subject who is refractory to previous analgesics for 12 weeks and more. Subject who is able and willing to complete all study related assessment tools and complied with scheduled clinic visits and clinical study procedures. Subject whose pain NRS ≧5 and PRSIS ≧1 at baseline (based on recall over the past week). Exclusion Criteria: Subject who, in the opinion of the investigator, was not likely to complete the trial for whatever reason. Subject who was treated with Pregabalin within the past 12 weeks (on baseline). Subject who has been regularly treated cervical pain with nerve blocks (such as stellate ganglion block, epidural block, radicular block and trigger point injection etc.).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02868359